Gt Biopharma Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Gt Biopharma Inc 's ROA in the second quarter of 2026?
Gt Biopharma Inc recorded a cumulative net loss of $-29 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -387.33%.

However, within the Healthcare sector 898 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4649, from total ROA ranking in the first quarter of 2026 at 5391.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	276.07 %	91.54 %	-36.07 %	-23.13 %	-73.11 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-29	-54	-52	-26	-38
Return On Assets (TTM)	-387.33 %	-977.3 %	-1129.47 %	-508.76 %	-665.58 %
GTBP's Total Ranking	# 4649	# 5391	# 4755	# 4847	# 4751
Total Assets (TTM) in million	10	8	4	7	3
Seq. Total Assets Change	23.32 %	87.6 %	-39.35 %	168.02 %	-37.19 %
Seq. Net Income Change	-	-	-	-	-

GTBP's 5 Years Annual ROA >> Back to GTBP Management Effectiveness >> Compare GTBP ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 428
Sector	# 899
Overall	# 4541

Return On Assets Statistics
High	Average	Low
23312.86 %	364.61 %	-12341.51 %
(Sep 30 2013)		(Jun 30 2017)

Financial Statements
Gt Biopharma Inc 's Assets	$ 10 million	GTBP's Balance sheet
Gt Biopharma Inc 's Income	$ -5 million	Quarterly GTBP's Income Statement
GTBP's Income by Division		See GTBP's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	91.54 %	-69.89 %	-15.18 %	-91.37 %	3291.93 %
Total Assets in million	8	4	14	17	192
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-34	-13	-8	-21	-58
Annual Return On Assets	-424.98 %	-311.01 %	-54.05 %	-126.03 %	-30.21 %

GTBP's 5 Years Annual ROA >> Back to GTBP Management Effectiveness >> Compare GTBP ROA to its Competitors

More Return On Assets Ratios
GTBP's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
GTBP's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for GTBP's Competitors
Subscribers only: Roa for Gt Biopharma Inc 's Suppliers
Subscribers only: Return On Assets for GTBP's Customers

You may also want to know
GTBP's Roi	GTBP's Inventory Turnover Ratio	GTBP's Growth Rates	GTBP's Dividend Comparisons
	GTBP's Profitability Ratios	GTBP's Asset Turnover Ratio	GTBP's Dividend Growth
GTBP's Roe	GTBP's Valuation Ratios	GTBP's Financial Strength Ratios	GTBP's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:27:16+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.